Skip to Content

Join the 'Glimepiride / Rosiglitazone' group to help and get support from people like you.

Glimepiride / Rosiglitazone News

Dealing With Diabetes Distress

Posted 16 Feb 2017 by Drugs.com

THURSDAY, Feb. 16, 2017 – People with diabetes have to think about their condition and make treatment decisions constantly – and all that extra work and worry can lead to psychological distress at times. "Diabetes distress" isn't the same as depression, however, diabetes experts note. It's a condition unique to the 24/7 demands that come with diabetes, particularly for people dependent on insulin. "The day you develop diabetes, it's like the universe just handed you a new full-time job that you have to do in addition to whatever else you're doing. It's a special job that has a big impact on the rest of your life. There's no pay and no vacation," said William Polonsky, president of the Behavioral Diabetes Institute in San Diego. Alicia McAuliffe-Fogarty, vice president of lifestyle management at the American Diabetes Association, put it this way: "Diabetes distress is the extra burden ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride, Pre-Diabetes, Novolin R, Amaryl

Is There a Link Between Diabetes and Pancreatic Cancer?

Posted 31 Jan 2017 by Drugs.com

TUESDAY, Jan. 31, 2017 – Developing or worsening type 2 diabetes could be an early sign of pancreatic cancer, new research suggests. Researchers analyzed data from nearly a million patients with type 2 diabetes or pancreatic cancer in Italy and Belgium. Half of all pancreatic cancer cases were diagnosed within a year of patients being diagnosed with diabetes, the findings showed. The investigators also found that type 2 diabetes patients whose condition deteriorated rapidly requiring more aggressive treatment were also at increased risk for pancreatic cancer. The study findings, which don't prove an association between type 2 diabetes and pancreatic cancer, were presented Monday at the European Cancer Congress (ECC) in Amsterdam. Research presented at medical meetings is typically considered preliminary until published in a peer-reviewed journal. "Doctors and their diabetic patients ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Glucophage, Glipizide, Novolog, Humalog, Janumet, Glyburide, Lantus Solostar, Levemir, Glimepiride, Pancreatic Cancer, Novolin R, Amaryl, Novolin N, Humulin N, Lantus Solostar Pen, Glucophage XR

Insulin Makers Conspired to Raise Prices: Lawsuit

Posted 31 Jan 2017 by Drugs.com

Three makers of insulin conspired to boost the prices of the lifesaving diabetes drug, according to a lawsuit filed Monday in federal court in Massachusetts. A recent study in the Journal of the American Medical Association said the price of insulin nearly tripled between 2002 and 2013, and three manufacturers – Sanofi, Novo Nordisk and Eil Lilly – have raised the list prices of their insulin in near unison, The New York Times reported. The price increases have triggered anger among patient groups and doctors, who say the rising cost of insulin appears to have little to do with higher production costs. "People who have to pay out of pocket for insulin are paying enormous prices, when they shouldn't be," Steve Berman, a lawyer for the patients, told The Times. The lawsuits alleges that the three companies increased the list prices on their insulin in order to win favor with pharmacy ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Lantus Solostar, Levemir, Actos, Pre-Diabetes, Glimepiride, Novolin R, Amaryl, Novolin N

Language Barrier May Keep Some Hispanics From Good Diabetes Care

Posted 23 Jan 2017 by Drugs.com

MONDAY, Jan. 23, 2017 – Hispanic-American type 2 diabetes patients who lack proficiency in English may end up with poorer care, a new study finds. Specifically, these patients were found to be much less likely than non-Hispanic patients to take newly prescribed diabetes medications as directed, the researchers said. The study "suggests that more needs to be done to improve adherence to newly prescribed medications among Latino patients at all levels of English proficiency," wrote a team led by Dr. Alicia Fernandez, of the University of California, San Francisco. A diabetes specialist who reviewed the study wasn't surprised by the results. The research "further validates what many clinicians already know: Patients who do not understand English tend to do worse with management of chronic disease," said Dr. Maria Pena. She is an endocrinologist who directs the Center for Weight Management ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Diabetes, Type 1, Glucophage, Novolog, Glipizide, Humalog, Insulin Resistance, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Pre-Diabetes, Glimepiride, Novolin R, Amaryl

Native Americans Make Progress Against Diabetes Complication

Posted 10 Jan 2017 by Drugs.com

TUESDAY, Jan. 10, 2017 – Diabetes-related kidney failure among Native American adults fell by more than half over almost 20 years, a U.S. Centers for Disease Control and Prevention report shows. The change is due to improvements in diabetes and kidney care, according to the report. The new research also found that among these patients, blood sugar control improved 10 percent between 1996 and 2014, and the use of medicine to protect kidneys rose from 42 percent to 74 percent over 5 years. Average blood pressure in Native Americans with diabetes and high blood pressure was well controlled (133/76 in 2015), the findings showed. In addition, more than 60 percent of Native Americans aged 65 and older with diabetes had a urine test for kidney damage in 2015, compared with 40 percent of Medicare patients with diabetes in 2013, the researchers said. "The Indian Health Service (IHS) has made ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Renal Failure, Glucophage, Glipizide, Novolog, Humalog, Insulin Resistance, Janumet, Glyburide, Lantus Solostar, Levemir, Pre-Diabetes, Glimepiride, Chronic Kidney Disease, Novolin R, Amaryl, Novolin N

Metformin Still Best Choice for First Type 2 Diabetes Treatment

Posted 3 Jan 2017 by Drugs.com

MONDAY, Jan. 2, 2017 – Newly updated guidelines reaffirm that metformin is the first-line drug for people with type 2 diabetes, and that several other medications – including newer ones – can be added if needed. The recommendations come from the American College of Physicians (ACP). The American Academy of Family Physicians endorsed the new guidelines. The ACP updated the guidelines because of new research into diabetes drugs, and the U.S. Food and Drug Administration approval of new diabetes drugs. "Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications," ACP president Dr. Nitin Damle said in a college news release. "The escalating rates of obesity in the U.S. are increasing the incidence and prevalence of diabetes substantially. Metformin has ... Read more

Related support groups: Diabetes, Type 2, Metformin, Januvia, Glucophage, Glipizide, Janumet, Glyburide, Invokana, Actos, Glimepiride, Pre-Diabetes, Amaryl, Pioglitazone, Tradjenta, Avandia, Glucophage XR, GlipiZIDE XL, Farxiga, Glucotrol, Jardiance

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Saxenda, Janumet, Glyburide, Byetta, Invokana, Lantus Solostar, Bydureon, Levemir, Actos, Trulicity

Intensive Blood Sugar Control May Be Too Much for Some With Type 2 Diabetes

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Intensive treatment of blood sugar levels in some people with type 2 diabetes may cause serious complications, new research suggests. "In this study, we found that, particularly among older patients and patients with serious chronic conditions, intensive treatment nearly doubled the risk of severe hypoglycemia requiring medical attention, including hospitalization," said lead author Dr. Rozalina McCoy. She is an endocrinologist at the Mayo Clinic in Rochester, Minn. Hypoglycemia (low blood sugar) is a serious potential complication of diabetes treatment. The researchers said it can worsen quality of life and has been linked with cardiovascular events, dementia and death. The researchers reviewed information from more than 31,500 American adults. All had stable and controlled type 2 diabetes. None was taking insulin. None had a prior history of severe ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Dementia, Glucophage, Glipizide, Novolog, Humalog, Hypoglycemia, Janumet, Glyburide, Invokana, Lantus Solostar, Levemir, Actos, Glimepiride, Novolin R, Amaryl, Novolin N

Metformin Safer for Heart Than Other Common Type 2 Diabetes Drugs: Study

Posted 18 Apr 2016 by Drugs.com

MONDAY, April 18, 2016 – Metformin, the most frequently prescribed standalone drug for type 2 diabetes, is better for the heart than its closest competitors, a large analysis suggests. Metformin reduced the risk of dying from heart attack and stroke by about 30 percent to 40 percent compared with other commonly used drugs called sulfonylureas, such as glibenclamide, glimepiride, glipizide and tolbutamide, researchers report. "Pharmaceutical companies continue to make new drugs to reduce blood sugar and improve on safety concerns of the older drugs," said senior study author Dr. Shari Bolen. But, "while adults with diabetes often need more than one medication to control blood sugar, the newer medications do not appear to be safer than the older drugs," added Bolen. Metformin is still the safest and most effective type 2 diabetes medication, said Bolen. She is an assistant professor of ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glipizide, Janumet, Glimepiride, Amaryl, Prevention of Cardiovascular Disease, Glucophage XR, GlipiZIDE XL, Cardiovascular Risk Reduction, Glucotrol, ActoPlus Met, Glucotrol XL, Glumetza, Glyburide/Metformin, Janumet XR, Avandamet, Glucovance, Jentadueto

Cost of Insulin Rises Threefold in Just a Decade: Study

Posted 5 Apr 2016 by Drugs.com

TUESDAY, April 5, 2016 – Americans with diabetes who rely on insulin to keep their blood sugar levels in check are facing sticker shock: A new study finds the price of insulin has tripled in only 10 years. Moreover, since 2010, per-person spending on insulin in the United States was more than spending on all other diabetes drugs, the study found. "The cost of insulin has risen rapidly over the last few years," said study senior author Philip Clarke, a professor of health economics at the University of Melbourne in Australia. Clarke added there should be an assessment to see whether this price hike is justifiable in terms of improved clinical outcomes. One reason for the price climb, he said, is a switch from human insulins to analog insulins, which cost more but may offer additional benefits. Also, doctors are more apt to prescribe insulin for people with type 2 diabetes now, Clarke ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Diabetes, Type 1, Januvia, Glucophage, Diabetic Neuropathy, Glipizide, Novolog, Humalog, Saxenda, Insulin Resistance, Janumet, Diabetic Nerve Damage, Glyburide, Byetta, Bydureon, Invokana

More Evidence Diabetes Drug Actos Raises Bladder Cancer Risk a Bit

Posted 31 Mar 2016 by Drugs.com

WEDNESDAY, March 30, 2016 – More evidence linking the diabetes drug Actos to an increased risk of bladder cancer has surfaced in a new study that also finds the risk rises with increased use. Actos (pioglitazone) appears to increase risk of bladder cancer by 63 percent, Canadian researchers say. The findings, published March 30 in The BMJ, stem from an analysis of nearly 146,000 patients treated between 2000 and 2013. The data also showed that bladder cancer risk increases if Actos is used for more than two years, or if someone takes more than 28,000 milligrams over the course of their lives. The overall risk is small, however. Still, "the more you accumulate the drug into your system, the higher the risk," said senior researcher Laurent Azoulay, an associate professor of oncology at McGill University in Montreal. Azoulay and his colleagues did not find a similar link between bladder ... Read more

Related support groups: Diabetes, Type 2, Insulin Resistance, Actos, Pre-Diabetes, Pioglitazone, Diabetes Mellitus, Avandia, Bladder Cancer, ActoPlus Met, Avandamet, Abnormal Glucose Tolerance, Rosiglitazone, Metformin/Pioglitazone, Oseni, Alogliptin/pioglitazone, Glimepiride/Pioglitazone, ActosPlus Met, Avandaryl, Glimepiride/Rosiglitazone, Duetact

FDA Medwatch Alert: Rosiglitazone-containing Diabetes Medicines: Drug Safety Communication - FDA Eliminates the Risk Evaluation and Mitigation Strategy (REMS)

Posted 16 Dec 2015 by Drugs.com

ISSUE: FDA is eliminating the Risk Evaluation and Mitigation Strategy (REMS) for rosiglitazone-containing type 2 diabetes medicines, which are approved as Avandia, Avandamet, Avandaryl, and generics. The REMS is no longer necessary to ensure that the benefits of rosiglitazone medicines outweigh their risks. In 2013, FDA required removal of the prescribing and dispensing restrictions for rosiglitazone medicines after determining that data did not demonstrate an increased risk of heart attack with rosiglitazone medicines compared to the standard type 2 diabetes medicines metformin and sulfonylurea. FDA also required the drug manufacturers to provide educational training to health care professionals about the current state of knowledge regarding the heart risks of rosiglitazone medicines. Manufacturers have since fulfilled these requirements. FDA has continued monitoring these medicines ... Read more

Related support groups: Diabetes, Type 2, Avandia, Avandamet, Rosiglitazone, Glimepiride/Rosiglitazone, Avandaryl, Metformin/Rosiglitazone

Blood Thinner, Certain Diabetes Drugs Are a Bad Combo

Posted 8 Dec 2015 by Drugs.com

TUESDAY, Dec. 8, 2015 – Taking the blood thinner warfarin at the same time as certain diabetes drugs increases the risk of hospitalization, a new study warns. Researchers analyzed data from nearly 466,000 Medicare patients. They found that those who took warfarin along with the diabetes drugs glipizide or glimepiride – also known as sulfonylureas – had a 22 percent increased risk of making an emergency room visit or being hospitalized for low blood sugar (hypoglycemia). While doctors are warned about potential interaction between the drugs, there has been little actual data, said study author John Romely, an associate professor at the University of Southern California Center for Health Policy and Economics and School of Public Policy. "Until now, no one had really studied the interactions between them," he said in a university news release. The risk was especially high for men aged ... Read more

Related support groups: Diabetes, Type 2, Warfarin, Coumadin, Glipizide, Glyburide, Glimepiride, Amaryl, GlipiZIDE XL, Glucotrol, Glucotrol XL, Jantoven, DiaBeta, Glynase, Micronase, Glipizide/Metformin, Glycron, Tolazamide, Chlorpropamide, Glimepiride/Pioglitazone, Diabinese

New Diabetes Cases Among Americans Drop for First Time in Decades: CDC

Posted 1 Dec 2015 by Drugs.com

TUESDAY, Dec. 1, 2015 – In a sign that Americans may finally be turning the corner in the fight against diabetes – and possibly obesity – federal health statistics released Tuesday show that the number of new cases of diabetes has dropped for the first time in decades. The decline wasn't sudden or dramatic. But, the number of new diabetes cases went from 1.7 million in 2009 to 1.4 million in 2014, according to the U.S. Centers for Disease Control and Prevention. "It seems pretty clear that incidence rates have now actually started to drop. Initially it was a little surprising because I had become so used to seeing increases everywhere we looked," CDC researcher Edward Gregg told The New York Times. The proportion of Americans with diabetes is still twice what it was in the early 1990s. And not every racial group has made strides against the blood sugar disease, which is often ... Read more

Related support groups: Obesity, Diabetes, Type 2, Metformin, Insulin, Weight Loss, Victoza, Lantus, Januvia, Glucophage, Glipizide, Novolog, Humalog, Saxenda, Janumet, Glyburide, Byetta, Bydureon, Invokana, Lantus Solostar, Levemir

Too Many Seniors With Diabetes Are Overtreated, Study Suggests

Posted 29 Oct 2015 by Drugs.com

THURSDAY, Oct. 29, 2015 – When it comes to treating seniors with diabetes, new research suggests that doctors often don't cut back on medications, even when treatment goals are surpassed. The study found that when people had potentially dangerous low blood sugar levels, just 27 percent had their medicines decreased. And when blood pressure treatments lowered blood pressure levels too much, just 19 percent saw a reduction in their medications. "As people get older, the risks of overtreating become greater, and the benefits become shorter. We have to start emphasizing that more isn't always better," said study author Dr. Jeremy Sussman, an assistant professor of internal medicine at the University of Michigan in Ann Arbor and a primary care doctor at the Ann Arbor VA System. The findings were published online Oct. 26 in the journal JAMA Internal Medicine. Practice guidelines generally ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Glipizide, Novolog, Humalog, Saxenda, Janumet, Glyburide, Byetta, Bydureon, Invokana, Lantus Solostar, Levemir, Actos, Trulicity

Page 1 2 3 Next

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2

Related Drug Support Groups

Avandaryl

Glimepiride / Rosiglitazone Patient Information at Drugs.com